Table 5.

Tabular summary

Tazarotene
First approved in Germany	1997 (psoriasis vulgaris)
Recommended control parameters	Check development of skin irritations
Recommended initial dosage	Begin with one treatment daily of tazarotene gel 0.05% in the evening for approximately 1–2 weeks
Recommended maintenance dosage	If necessary continue for 1–2 weeks with tazarotene gel 0.1%
Expected beginning of clinical effect	After 1–2 weeks
Response rate	After 12 weeks therapy with 0.1% tazarotene gel improved findings of at least 50% in approximately 50% of the patients (LE 2)
Important contraindications	Pregnancy, nursing
Important ADRs	Pruritus, burning sensation of skin, erythema, irritation
Important drug interactions	Avoid concomitant use of preparations with irritating and drying properties
Other	–